PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26121139-0	2015	Channel Activity of Cardiac Ryanodine Receptors (RyR2) Determines Potency and Efficacy of Flecainide and R-Propafenone against Arrhythmogenic Calcium Waves in Ventricular Cardiomyocytes.	Propafenone	105-118	ryanodine receptor 2, cardiac	Mus musculus	49-53	
26121139-2	2015	We hypothesized that differences in RyR2 activity induced by CPVT mutations determines the potency of open-state RyR2 blockers like flecainide (FLEC) and R-propafenone (RPROP) against Ca2+ waves in cardiomyocytes.	Propafenone	154-167	ryanodine receptor 2, cardiac	Mus musculus	36-40	
26121139-2	2015	We hypothesized that differences in RyR2 activity induced by CPVT mutations determines the potency of open-state RyR2 blockers like flecainide (FLEC) and R-propafenone (RPROP) against Ca2+ waves in cardiomyocytes.	Propafenone	154-167	ryanodine receptor 2, cardiac	Mus musculus	113-117	
26121139-2	2015	We hypothesized that differences in RyR2 activity induced by CPVT mutations determines the potency of open-state RyR2 blockers like flecainide (FLEC) and R-propafenone (RPROP) against Ca2+ waves in cardiomyocytes.	Propafenone	169-174	ryanodine receptor 2, cardiac	Mus musculus	36-40	
26121139-2	2015	We hypothesized that differences in RyR2 activity induced by CPVT mutations determines the potency of open-state RyR2 blockers like flecainide (FLEC) and R-propafenone (RPROP) against Ca2+ waves in cardiomyocytes.	Propafenone	169-174	ryanodine receptor 2, cardiac	Mus musculus	113-117	
21270101-5	2011	Only flecainide and propafenone inhibited RyR2 channels, with the S-enantiomer of propafenone having a significantly lower potency than R-propafenone or flecainide.	Propafenone	20-31	ryanodine receptor 2, cardiac	Mus musculus	42-46	
24493699-9	2014	CONCLUSIONS: Loss of Casq2 increases risk of AF by promoting regional SCaEs and delayed afterdepolarizations in atrial tissue, which can be prevented by RyR2 inhibition with R-propafenone.	Propafenone	174-187	ryanodine receptor 2, cardiac	Mus musculus	153-157	
24493699-10	2014	Targeting AF caused by leaky RyR2 Ca channels with R-propafenone may be a more mechanism-based approach to treating this common arrhythmia.	Propafenone	51-64	ryanodine receptor 2, cardiac	Mus musculus	29-33	
21270101-5	2011	Only flecainide and propafenone inhibited RyR2 channels, with the S-enantiomer of propafenone having a significantly lower potency than R-propafenone or flecainide.	Propafenone	82-93	ryanodine receptor 2, cardiac	Mus musculus	42-46